Dr Tsuboi on Updated Survival Results of the ADAURA Trial in Resectable NSCLC

News
Video

Masahiro Tsuboi, MD, discusses the updated survival results of the phase 3 ADAURA trial in resectable EGFR-mutant non–small cell lung cancer.

Masahiro Tsuboi, MD, a surgeon at the National Cancer Center Hospital East in Japan, discusses the updated survival results of the phase 3 ADAURA trial (NCT02511106) in resectable EGFR-mutant non–small cell lung cancer.

Related Videos
Stephanie L. Graff, MD
Senthil Damodaran, MD, PhD
Eytan M. Stein, MD
Bradley Monk, MD, FACS, FACOG
Jason Jincong Freeman, PhD
Heather A. Parsons, MD, MPH
A panel of 5 experts on lung cancer seated at a long table
Joshua K. Sabari, MD, and Marina Chiara Garassino, MD, experts on non-small cell lung cancer
A panel of 5 experts on lung cancer
A panel of 5 experts on lung cancer
Related Content
David Harpole, MD

AEGEAN Subgroup Analysis Fails to Demonstrate Clear Benefit With Perioperative Durvalumab Plus Chemo in EGFR+ NSCLC

December 5th 2023
Article
Hari B. Keshava, MD

Keshava Emphasizes the Importance of Lung Nodule Programs for Early Lung Cancer Detection

October 23rd 2023
Podcast
FDA Grants Fast Track Designation to BI 764532 for DLL3+ Large-Cell NEC of the Lung

FDA Grants Fast Track Designation to BI 764532 for DLL3+ Large-Cell NEC of the Lung

December 4th 2023
Article
Adnan F. Danish, MD

Danish Discusses the Benefits of SCINTIX Biology-Guided Radiotherapy in Metastatic Lung and Bone Cancers

August 7th 2023
Podcast
Lyudmila A. Bazhenova, MD

Multidisciplinary Collaboration and Molecular Testing Are Integral to Treatment Decision-Making in NSCLC

November 30th 2023
Article
FDA

FDA Grants Clearance for Phase 1/2 Trial of eTIL KSQ-001EX in Solid Tumors

November 30th 2023
Article